WhaleQuant.io
Regeneron Pharmaceuticals, Inc. (REGN) Corporate Logo

Regeneron Pharmaceuticals, Inc. (REGN) Stock Price & Analysis

Market: NASDAQ • Sector: Healthcare • Industry: Biotechnology

Regeneron Pharmaceuticals, Inc. (REGN) Profile & Business Summary

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Key Information

Ticker REGN
Exchange NASDAQ
Official Site https://www.regeneron.com
CIK Number 0000872589
View SEC Filings

Market Trend Overview for REGN

One model, two time views: what the market looks like right now, and where the larger trend is heading over time.

Longer-Term Market Trend (Mid to Long Term)

Shows the bigger market trend, how strong it is, and where risks may start to build over the next few weeks or months. — Updated as of 2026-11-17 (ET)

As of 2026-11-17, REGN is moving sideways without a clear direction. Over the longer term, the trend remains bullish.

REGN last closed at 957.76. The price is about 1.8 ATR above its recent average price (920.67), and the market is currently in a sideways market without a clear direction. Price at 957.76 is moving between minor support near 898.29 and minor resistance near 981.55. Direction remains unclear. View Support & Resistance from Options

The market is moving sideways, with no clear direction. Both upside and downside risks remain in play.

Trend Alignment Summary

Trend score: 35 out of 100. Overall alignment is unclear. The market is currently in a sideways market without a clear direction. The longer-term trend is still positive, but short-term signals are not yet confirming it.

Key Risk Level

A key downside risk boundary is near 799.31. If price falls below this area, the current structure would likely weaken further.

Recent Trend Signal

A systematic trend-activation signal was most recently triggered on 2026-10-15, reflecting a technical shift toward positive directional alignment.

Unusual Price Movement

[2026-10-23] Price moved quickly and looked strong, but participation was limited.

Recent Price Behavior

Recent bars show mixed price behavior without a clear shift in structural quality or efficiency.

Overnight Positioning

There was no clear sign of meaningful positions being carried into the overnight session.

Next-day directional probability forecast Last updated: 2026-11-17 (ET)
Next-session outlook for 2026-11-18 (ET)
Mild bullish lean, but not actionable

What the model sees

The model still sees a directional lean, but the edge is not thick enough after adjusting for reward/risk.


Why the model says this

The model does not deploy this setup because the directional lean exists, but the edge is still not thick enough after risk adjustment, reward/risk remains too thin at 0.09 after adjustment, and recent price behavior has shown failed reversal memory. Predictability is 44%, agreement is 93%, and reversal risk is 13%.

NOTE: This next-day up/down probability forecast module is still being tested for accuracy. Please do not rely on it for investment decisions. The model does not account for black swan events or company-specific fundamental news, and its estimates are based solely on technical conditions, capital flow, and market sentiment. View forecast history

Recent Cost Distribution Last updated: 2026-11-17 (ET)

This estimate uses 1-minute price, volume, and VWAP data from the last 55 trading days, with turnover-based decay. The sample period is 2026-09-01 to 2026-11-17. The current price is 957.76, 12.90% above the estimated average cost of 848.30. An estimated 88.8% of recent positioning is below the current price, while 10.5% is above it. The peak-density price is 806.00. The largest concentrated cost region is 780.50 to 823.50 and contains 32.5% of the estimated distribution. The current price is within the 950.50 to 973.50 cost region. The nearest region below the current price is 943.50 to 946.50.

Short Interest & Covering Risk for REGN

This analysis looks at overall short interest positioning, focusing on the broader setup rather than short-term noise.

Squeeze Score 0.60

Shows how likely a short squeeze may be under current market conditions.

Key Market Risk Indicators
Short Crowding (Short Interest / Float) 2.23%
Short Positions Trend Increasing
Liquidity Trend (Average Daily Volume) 20.89%
20-Day Return 18.61%
Price vs 20-Day High Trading Near Highs

Short Exposure Percentile

Short interest is above its usual range, suggesting rising pressure on short positions, though not yet extreme. (Historical percentile: 60%)

Structure Analysis

REGN Short positioning looks normal. Current days to cover is 2.7 trading days, meaning short positions could unwind at a normal pace. Short covering is likely to have a normal impact on price moves. No meaningful structural fragility is currently detected (Fragility Score 13/100, DTC percentile 30%) despite a strong upward price move (20D return 18.6%) with short positioning continuing to expand.

Risk Summary

No clear bull trap characteristics detected. Recent price behavior remains broadly consistent with current positioning.This reading helps confirm that current price action remains structurally healthy and does not indicate elevated trap risk.

Why Price Reactions May Be Stronger?

In the latest reporting period, short interest continues to increase. Adaptive thresholds applied to liquidity weakness, near-high detection, and compression sensitivity. As a result, similar news or market events could lead to price moves about 1× larger than usual.


Note: Short interest data is reported every two weeks by FINRA. The most recent snapshot is 2026-10-30 (ET).
Because this data updates slowly, it is not intended to predict short-term price moves. Instead, it helps describe longer-term market structure and where pressure may be building if prices begin to move.

Analytical Modules